Galderma has reported new interim analysis data from the OLYMPIA trial of Nemluvio for the moderate-to-severe prurigo ...

An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory ...

Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in ...

Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...